225 related articles for article (PubMed ID: 21364978)
1. Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance.
Hensley SE; Das SR; Gibbs JS; Bailey AL; Schmidt LM; Bennink JR; Yewdell JW
PLoS One; 2011 Feb; 6(2):e15190. PubMed ID: 21364978
[TBL] [Abstract][Full Text] [Related]
2. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
Ferraris O; Escuret V; Bouscambert-Duchamp M; Lina B; Morfin F
Pathol Biol (Paris); 2010 Apr; 58(2):e69-78. PubMed ID: 20303677
[TBL] [Abstract][Full Text] [Related]
3. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
Stoner TD; Krauss S; DuBois RM; Negovetich NJ; Stallknecht DE; Senne DA; Gramer MR; Swafford S; DeLiberto T; Govorkova EA; Webster RG
J Virol; 2010 Oct; 84(19):9800-9. PubMed ID: 20660186
[TBL] [Abstract][Full Text] [Related]
4. Secondary substitutions in the hemagglutinin and neuraminidase genes associated with neuraminidase inhibitor resistance are rare in the Influenza Resistance Information Study (IRIS).
Roosenhoff R; Schutten M; Reed V; Clinch B; van der Linden A; Fouchier RAM; Fraaij PLA
Antiviral Res; 2021 May; 189():105060. PubMed ID: 33713731
[TBL] [Abstract][Full Text] [Related]
5. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
[TBL] [Abstract][Full Text] [Related]
6. Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody.
Prachanronarong KL; Canale AS; Liu P; Somasundaran M; Hou S; Poh YP; Han T; Zhu Q; Renzette N; Zeldovich KB; Kowalik TF; Kurt-Yilmaz N; Jensen JD; Bolon DNA; Marasco WA; Finberg RW; Schiffer CA; Wang JP
J Virol; 2019 Jan; 93(2):. PubMed ID: 30381484
[TBL] [Abstract][Full Text] [Related]
7. Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.
Ilyushina NA; Govorkova EA; Gray TE; Bovin NV; Webster RG
PLoS Pathog; 2008 Apr; 4(4):e1000043. PubMed ID: 18404209
[TBL] [Abstract][Full Text] [Related]
8. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of the enhanced viral fitness contributed by secondary mutations in the hemagglutinin protein of oseltamivir resistant H1N1 influenza viruses: modeling studies of antibody and receptor binding.
Behera AK; Basu S; Cherian SS
Gene; 2015 Feb; 557(1):19-27. PubMed ID: 25479009
[TBL] [Abstract][Full Text] [Related]
10. Early findings of oseltamivir-resistant pandemic (H1N1) 2009 influenza A viruses in Taiwan.
Yang JR; Huang YP; Lin YC; Su CH; Kuo CY; Hsu LC; Wu HS; Liu MT
Antiviral Res; 2010 Dec; 88(3):256-62. PubMed ID: 20869989
[TBL] [Abstract][Full Text] [Related]
11. Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019.
Tang J; Zhang SX; Zhang J; Li XY; Zhou JF; Zou SM; Bo H; Xin L; Yang L; Liu J; Huang WJ; Dong J; Wang DY
Virology; 2020 Oct; 549():77-84. PubMed ID: 32853849
[TBL] [Abstract][Full Text] [Related]
12. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.
Matsuzaki Y; Mizuta K; Aoki Y; Suto A; Abiko C; Sanjoh K; Sugawara K; Takashita E; Itagaki T; Katsushima Y; Ujike M; Obuchi M; Odagiri T; Tashiro M
Virol J; 2010 Mar; 7():53. PubMed ID: 20202225
[TBL] [Abstract][Full Text] [Related]
13. Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
Choi WS; Jeong JH; Kwon JJ; Ahn SJ; Lloren KKS; Kwon HI; Chae HB; Hwang J; Kim MH; Kim CJ; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046464
[TBL] [Abstract][Full Text] [Related]
14. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.
Tamura D; Sugaya N; Ozawa M; Takano R; Ichikawa M; Yamazaki M; Kawakami C; Shimizu H; Uehara R; Kiso M; Kawakami E; Mitamura K; Kawaoka Y
Clin Infect Dis; 2011 Feb; 52(4):432-7. PubMed ID: 21248368
[TBL] [Abstract][Full Text] [Related]
15. I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y.
LeGoff J; Rousset D; Abou-Jaoudé G; Scemla A; Ribaud P; Mercier-Delarue S; Caro V; Enouf V; Simon F; Molina JM; van der Werf S
PLoS One; 2012; 7(8):e37095. PubMed ID: 22936969
[TBL] [Abstract][Full Text] [Related]
16. Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.
Fujisaki S; Imai M; Takashita E; Taniwaki T; Xu H; Kishida N; Yokoyama M; Sato H; Tashiro M; Odagiri T
J Infect Chemother; 2013 Oct; 19(5):891-5. PubMed ID: 23529501
[TBL] [Abstract][Full Text] [Related]
17. Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
Tamura D; DeBiasi RL; Okomo-Adhiambo M; Mishin VP; Campbell AP; Loechelt B; Wiedermann BL; Fry AM; Gubareva LV
J Infect Dis; 2015 Oct; 212(8):1209-13. PubMed ID: 25943200
[TBL] [Abstract][Full Text] [Related]
18. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus.
Kiso M; Ozawa M; Le MT; Imai H; Takahashi K; Kakugawa S; Noda T; Horimoto T; Kawaoka Y
J Virol; 2011 May; 85(10):4667-72. PubMed ID: 21367898
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient.
Abed Y; Schibler M; Checkmahomed L; Carbonneau J; Venable MC; Fage C; Giannotti F; Goncalves AR; Kaiser L; Boivin G
Antivir Ther; 2019; 24(8):581-587. PubMed ID: 32031540
[TBL] [Abstract][Full Text] [Related]
20. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
